SEC Form SC 13G filed

2/16/21 11:40:40 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $SRPT alert in real time by email

SC 13G 1 srpt12312020.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ------------------------------------------------------------------------------- SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO Section 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO Section 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No.1) SAREPTA THERAPEUTICS INC ---------------------------------------------- (Name of Issuer) COMMON STOCK ----------------------------------------------- (Title of Class of Securities) 803607100 --------------------- (CUSIP Number) DECEMBER 31, 2020 --------------------- (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Page 1 of 5 Pages ------------------------------------------------------------------------------- CUSIP No.: 803607100 13G Page 2 of 5 Pages ................................................................................ 1. Names of Reporting Persons Sands Capital Management, LLC ................................................................................ 2. Check the Appropriate Box if a Member of a Group (a) [ ] (b) [ ] NOT APPLICABLE ................................................................................ 3. SEC Use Only ................................................................................ 4. Citizenship or Place of Organization Delaware, United States ................................................................................ Number of 5. Sole Voting Power: 700,354 Shares Beneficially ................................................................ Owned by Each Reporting 6. Shared Voting Power: -0- Person With ................................................................ 7. Sole Dispositive Power: 977,131 ................................................................ 8. Shared Dispositive Power: -0- ................................................................................ 9. Aggregate Amount Beneficially Owned by Each Reporting Person 977,131 ................................................................................ 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares [ ] NOT APPLICABLE ................................................................................ 11. Percent of Class Represented by Amount in Row (9) 1.24% ................................................................................ 12. Type of Reporting Person: IA ______________________________ ------------------------------------------------------------------------------- CUSIP No.: 803607100 13G Page 3 of 5 Pages Item 1(a) Name of Issuer: SAREPTA THERAPEUTICS INC Item 1(b) Address of Issuer's Principal Executive Offices: 215 FIRST STREET, SUITE 415, CAMBRIDGE, MA 02142 Item 2(a) Name of Person Filing: SANDS CAPITAL MANAGEMENT, LLC Item 2(b) Address of Principal Business Office, or if None, Residence: 1000 WILSON BLVD., SUITE 3000, ARLINGTON, VA 22209 Item 2(c) Citizenship: DELAWARE, UNITED STATES Item 2(d) Title of Class of Securities: COMMON STOCK Item 2(e) CUSIP Number: 803607100 Item 3 If this statement is filed pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); (b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); (d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8); (e) [X] An investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F); (g) [ ] A parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G); (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3); (j) [ ] A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J); (k) [ ] Group, in accordance with Section 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____ ------------------------------------------------------------------------------- CUSIP No.: 803607100 13G Page 4 of 5 Pages Item 4. Ownership Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 977,131 (b) Percent of class: 1.24% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 700,354 (ii) Shared power to vote or to direct the vote: None (iii) Sole power to dispose or to direct the disposition of: 977,131 (iv) Shared power to dispose or to direct the disposition of: None Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ X ]. Item 6. Ownership of More than Five Percent on Behalf of Another Person Not Applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person. Not Applicable. Item 8. Identification and Classification of Members of the Group. Not Applicable. Item 9. Notice of Dissolution of Group. Not Applicable. ------------------------------------------------------------------------------- CUSIP No.: 803607100 13G Page 5 of 5 Pages Item 10 Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Section 240.14a-11. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Sands Capital Management, LLC Date: February 16, 2021 By: /s/ Lisa M. Grozio ---------------------- Name: Lisa M. Grozio Title: Chief Compliance Officer

Get the next $SRPT alert in real time by email

Recent Analyst Ratings for

$SRPT

Date	Price Target	Rating	Analyst
5/8/2025	$50.00	Outperform → In-line	Evercore ISI
4/11/2025	$115.00	Overweight	Wells Fargo
4/2/2025	$75.00	Sell → Neutral	H.C. Wainwright
3/31/2025	$161.00 → $87.00	Outperform → Sector Perform	RBC Capital Mkts
2/11/2025	$136.00	Hold	Deutsche Bank
11/27/2024	$205.00 → $202.00	Buy	Needham
11/25/2024	$80.00	Sell	H.C. Wainwright
11/7/2024	$152.00 → $167.00	Neutral → Overweight	Cantor Fitzgerald

More analyst ratings

SEC Form SC 13G filed

Chat with this insight

Recent Analyst Ratings for $SRPT

$SRPT Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Sarepta Therapeutics Inc.

SEC Form SC 13G filed by Sarepta Therapeutics Inc.

SEC Form SC 13G/A filed by Sarepta Therapeutics Inc. (Amendment)

$SRPT Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Nicaise Claude exercised 9,746 shares at a strike of $25.18 and sold $248,203 worth of shares (2,491 units at $99.64), increasing direct ownership by 35% to 27,812 units (SEC Form 4)

Director Boor Kathryn Jean was granted 2,383 shares, increasing direct ownership by 41% to 8,263 units (SEC Form 4)

Director Connelly Deirdre P was granted 2,383 shares, increasing direct ownership by 84% to 5,225 units (SEC Form 4)

$SRPT Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Sarepta Therapeutics downgraded by Evercore ISI with a new price target

Wells Fargo initiated coverage on Sarepta Therapeutics with a new price target

Sarepta Therapeutics upgraded by H.C. Wainwright with a new price target

$SRPT Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Chambers Michael Andrew bought $4,955,728 worth of shares (37,038 units at $133.80) (SEC Form 4)

Barry Richard bought $3,940,500 worth of shares (50,000 units at $78.81) (SEC Form 4)

Ingram Douglas S bought $2,001,800 worth of shares (25,225 units at $79.36), increasing direct ownership by 7% to 390,307 units (SEC Form 4)

$SRPT Press Releases

Fastest customizable press release news feed in the world

Sarepta Therapeutics to Present at the BofA Securities Health Care Conference

Sarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate Developments

Sarepta Therapeutics to Announce First Quarter 2025 Financial Results

$SRPT Leadership Updates

Live Leadership Updates

Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors

Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives

Sarepta Therapeutics Set to Join S&P MidCap 400

$SRPT SEC Filings

SEC Form 10-Q filed by Sarepta Therapeutics Inc.

SEC Form DEFA14A filed by Sarepta Therapeutics Inc.

SEC Form DEF 14A filed by Sarepta Therapeutics Inc.

$SRPT Financials

Live finance-specific insights

Sarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate Developments

Sarepta Therapeutics to Announce First Quarter 2025 Financial Results

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Recent Corporate Developments

$SRPT FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for AMONDYS 45 issued to SAREPTA THERAPS INC

June 20, 2024 - FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy

FDA Approval for VYONDYS 53 issued to SAREPTA THERAPS INC

Recent Analyst Ratings for
$SRPT

$SRPT
Large Ownership Changes

$SRPT
Insider Trading

$SRPT
Analyst Ratings

$SRPT
Insider Purchases

$SRPT
Press Releases

$SRPT
Leadership Updates

$SRPT
SEC Filings

$SRPT
Financials

$SRPT
FDA approvals